NaDeNo

2 known investors

NaDeNo develops nanoparticle-based drug delivery technology for local, targeted and controlled release of hard-to-deliver molecules, and offers its platform to pharma and biotech companies. Its lead asset, PACAB-002, is a therapeutic designed to prevent recurrence in high-grade serous ovarian cancer by eradicating residual peritoneal micrometastases, with a Phase 1 trial planned for early 2027.